PM-OICR Translational Genomics Laboratory - Homepage

About Us


The Princess Margaret Cancer Centre-Ontario Institute for Cancer Research Translational Genomics Lab (PM-OICR TGL) is a joint collaborative workspace located in the MaRS complex at University Avenue and College Street in downtown Toronto. TGL enhances rapid access to genomics technologies, and facilitates genomic interpretation and reporting in clinical oncology. TGL provides research support to the Princess Margaret Cancer Centre and affiliated cancer research institutions as part of OICR’s Adaptive Oncology Program.

TGL is formulated to accelerate clinical oncology research through partnership and drive key initiatives:

  • Facilitate access to genome-wide multi-omic assays from pathology specimens (Formalin Fixed Paraffin Embedded, FFPE);
  • Identify molecular patterns associated with patient outcome and clinical variables from standard of care and second line therapies;
  • Share and continuously improve integrated analysis methods Github to facilitate robust tumor phenotypic classification;
  • Facilitate actionable mutation detection through an emphasis on multiplatform molecular diagnostics, including methylation, transcriptome and exome sequencing;
  • Integrate variant reporting into work streams through cBioPortal and Heliotrope, allowing rapid, automated dissemination of results to the oncologic community and research databases, including ICGCmed.

TGL participates in clinical trial research through the Princess Margaret Cancer Genomics (CGP) and Tumor Immunotherapy Programs (TIP) providing extended capabilities and infrastructure. TGL is supporting the Ontario-wide Targeted Nucleic Acid Evaluation (OCTANE) Trial, which is increasing cancer patient access to next-generation sequencing (NGS) technology and rapid informatic analysis in therapeutic management. OCTANE is establishing large provincial cohorts of consented patients for NGS-based genomic profiling that may inform the use of approved therapies and identify patients that may benefit from advanced molecular profiling within TGL. TGL participates in a variety of clinical research studies including; Genomic Investigation of Unusual Responders (GENIUS), Integrative Sequencing in Germline and Hereditary Tumors (INSIGHT), Comprehensive Translational Research Study of Head and Neck Tumors, Determinants of Outcome in Medulloblastoma and Ependymoma in Ontario, Accelerated Identification and Validation of Novel Molecular Signatures to Improve Treatment in Early Stage Non-small Cell Lung Cancer Patients, Retrospective Analysis of Cloncal Evolution and Tumor Heterogeneity from IMPACT (REACT), Investigator Initiated Phase II Study of Pembrolizumab Immunological Response Evaluation (INSPIRE), Biallelic Mismatch Repair Deficiency Syndrome (bMMRD), Novel Universal Classification of Childhood Low Grade Gliomas using Clinico-pathological and Molecular Methods, Comprehensive Genomic Characterization of Lung Adenocarcinoma in Never Smokers, Treatment-free Remission Accomplished with Dasatinib in Patients with CML, Molecular Testing of Tumor Samples as a Classification Tool, An Open-label, Phase Baseket Study of Hypomethylating Agent Oral Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR), plus many more! TGL prioritizes research-grade lab and computational capabilities to advance, validate and translate robust protocols for integration by clinical laboratories (College of American Pathologist (CAP), Clinical Laboratory Improvement Amendments (CLIA), Ontario Laboratory Accreditation (OLA)) in the Ontario healthcare community.

Contact The PM-OICR Translational Genomics Laboratory

Dax Torti

Project Manager
PM-OICR Translational Genomics Lab

Email: dax [dot] tortiatoicr [dot] on [dot] ca

Phone: 647-260-7938

Ontario Institute for Cancer Research (OICR)
MaRS Centre
661 University Avenue
Toronto, Ontario M5G 0A3
Canada